HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available starting March 09, 2021, at 7:00 AM ET via a webcast on HOOKIPA's official website. The company is focused on developing immunotherapeutics using its proprietary arenavirus platform, targeting cancers and infectious diseases. Notably, their product candidates, HB-201 and HB-202, are in Phase 1/2 trials for HPV-positive cancers, while HB-101 is in a Phase 2 trial for kidney transplant patients.

NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the upcoming H.C. Wainwright Global Life Sciences Conference held virtually from March 9-10, 2021:

Presentation: The conference is being conducted in a virtual format and a webcast of the presentation will become available on Tuesday, March 09, 2021 at 7:00 AM ET

The webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.  

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. Our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. 

HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.  

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic hepatitis B infections. 

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:
Media	Investors
Nina Waibel	Matt Beck
Senior Director - Communications	Executive Director - Investor Relations
nina.waibel@hookipapharma.com	matthew.beck@hookipapharma.com

FAQ

When is the H.C. Wainwright Global Life Sciences Conference for HOOK?

The conference will take place virtually on March 9-10, 2021.

What is HOOKIPA Pharma presenting at the conference?

HOOKIPA will present updates on its proprietary arenavirus platform and clinical trials for its immunotherapeutics.

Where can I watch HOOKIPA's conference presentation?

The presentation will be available on HOOKIPA's website starting March 09, 2021, at 7:00 AM ET.

What is the focus of HOOKIPA's drug development?

HOOKIPA focuses on developing immunotherapeutics targeting cancer and infectious diseases using its arenavirus platform.

What clinical trials are HOOKIPA's product candidates undergoing?

HB-201 and HB-202 are in Phase 1/2 trials for HPV-positive cancers, while HB-101 is in a Phase 2 trial for kidney transplantation.